Prostate cancer is the most common cancer and the third leading cause of cancer-specific death in men in Western industrialized countries.
Implementation of the prostate-specific antigen (PSA) blood test as an early detection tool has led to a significant reduction of prostate cancer mortality in the USA. Apart from an earlier detection of clinically relevant tumors, regular PSA testing increases the risk of over-detection and over-treatment of clinically indolent tumors. In our view, a reliable stratification of indolent tumors in active surveillance programs is the key in avoiding or reducing overtreatment of early diagnosed prostate cancers. Along with better risk stratification, the expansion of PSA screening should be discussed in order to reduce the still high numbers of palliative treatments, metastases, and prostate cancer-related deaths.
Written by:
Graefen M, Schlomm T, Steuber T, Sauter G. Are you the author?
Martini-Klinik, Prostatakarzinomzentrum am UKE, Universitätsklinikum Hamburg-Eppendorf, Martinistr. 52, 20246, Hamburg, Deutschland.
Reference: Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2014 Mar;57(3):312-7.
doi: 10.1007/s00103-013-1905-0
PubMed Abstract
PMID: 24562706
Article in German.
UroToday.com Prostate Cancer Section
